Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

Researchers present exosome-mediated system delivery of therapeutic cargo for HIV-1 repression

Dec. 23, 2021

CRISPR-Cas9 gRNA system eliminates diverse proviral HIV-1 strains

Dec. 10, 2021

New nanoformulation provides a promising candidate for long-acting dosing of tenofovir

Oct. 28, 2021

ViiV Healthcare discloses new anti-HIV compounds

Oct. 6, 2021

Shionogi licenses S-365598 to ViiV for use in ultra long-acting HIV regimens

Sep. 29, 2021

Selective functional impairment of HIV-specific CD8+ T cells heralds aborted HIV control

Sep. 28, 2021

New HIV replication inhibitors discovered at Gilead

Sep. 21, 2021

Pharmasyntez JSC identifies HIV-1 reverse transcriptase/ribonuclease H inhibitors

Sep. 16, 2021

Green light for UB-421 phase II studies in Taiwan and China for HIV

Aug. 19, 2021

Ghent University Hybrid CAR-T cell platform has dual anti-HIV effects

July 28, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
IMV-101 shows promise for B-cell malignancies
BioWorld Science
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...